Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study led by researchers at Vanderbilt University Medical Center.
While their report, published Nov. 4 in the journal Cell, focused on development of antibody therapeutics against existing and emerging viral threats, including RSV (respiratory syncytial virus) and avian influenza viruses, the implications of the research are much broader, said the paper’s corresponding author, Ivelin Georgiev, PhD.
“This study is an important early milestone toward our ultimate goal — using computers to efficiently and effectively design novel biologics from scratch and translate them into the clinic,” said Georgiev, professor of Pathology, Microbiology and Immunology, and director of the Vanderbilt Program in Computational Microbiology and Immunology.
“Such approaches will have significant positive impact on public health and can be applied to a broad range of diseases, including cancer, autoimmunity, neurological diseases, and many others,” he said.
Georgiev is a leader in the use of computational approaches to advance disease treatment and prevention. He is the principal investigator of an up to $30 million award from the Advanced Research Projects Agency for Health (ARPA-H) to support the application of AI technology that can develop novel antibodies with therapeutic potential.
Perry Wasdin, PhD, a data scientist in the Georgiev lab, was involved in all aspects of the study and is first author of the paper.
The research team, which included scientists from around the country, Australia and Sweden, showed that a protein language model could design functional human antibodies that recognized the unique antigen sequencies (surface proteins) of specific viruses, without requiring part of the antibody sequence as a starting template.